Trial Profile

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ingenol disoxate (Primary)
Indications Actinic keratosis
Focus Adverse reactions; Therapeutic Use
Sponsors LEO Pharma

Most Recent Events

12 Jan 2017 Results assessing efficacy and tolerability published in the British Journal of Dermatology (2017).
08 Mar 2016 Primary endpoint has been met. (Part 2: Reduction in AK count), as per results presented at the 74th Annual Meeting of the American Academy of Dermatology.
08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com